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Global disparities in HPV vaccination
Cervical cancer is the fourth most common cancer in 
women globally, but remains the second most common 
cancer (after breast cancer) in many low-income and 
middle-income countries, and is still more common 
than breast cancer in sub-Saharan Africa.1 Most new 
cervical cancer cases (85%) and deaths (88%) occur in 
low-income and middle-income countries, where health 
systems are often fragmented or fragile, and where 
most have not yet implemented eﬀ ective national 
cervical cancer screening programmes. Deaths from 
cervical cancer continue to be a largely preventable 
tragedy for more than 266 000 women and their 
families every year.1 
Since 2006, many countries have adopted national 
immunisation policies for human papillomavirus 
(HPV), and the work of GAVI, the Vaccine Alliance, 
and the Revolving Fund of the Pan American Health 
Organization, have created opportunities for many 
countries to access HPV vaccines at reduced prices. 
Under the auspices of GAVI and several civil society 
organisations, many girls have been immunised through 
demonstration projects. However, to what extent these 
eﬀ orts have led to improved immunisation coverage 
remains unclear.
In The Lancet Global Health, Laia Bruni and colleagues2 
shed new light on the status of national HPV 
immunisation programmes, and emphasise both the 
global disparities and the tremendous potential to 
vastly improve cervical cancer control, particularly in 
regions with high incidence and limited cervical cancer 
screening programmes.
The investigators developed a novel method to 
identify HPV immunisation programmes worldwide 
by combining systematic review of the literature and 
oﬃ  cial web-based data, from which they retrieved age-
speciﬁ c vaccination coverage. These coverage rates 
were then converted into birth-cohort-speciﬁ c rates, 
applied to country burden estimates, and presented 
in terms of cases and deaths averted, according to 
country income category. The investigators estimate 
that, although 118 million girls were targeted 
through HPV immunisation programmes from June, 
2006, to October, 2014, only 1% were from low-
income or lower-middle-income countries. Although 
47 million (95% CI 39–55 million) girls and women 
aged 10–20 years received the full course of vaccine, 
and 59 million (48–71 million) received at least one 
dose, only 2·7% (1·8–3·6) of these females were living 
in less developed regions. Therefore, countries with the 
highest burdens of disease remain largely unprotected. 
The methods presented by Bruni and colleagues 
have limitations; however, manufacturer reports of 
175 million doses distributed by 2014, suggest that 
their estimates are unlikely to be substantially imprecise. 
Better reporting by countries, and methods to 
objectively and independently validate these data, will 
be important going forward, and the investigators have 
developed an innovative approach to assist countries in 
tracking progress over time. 
As the investigators emphasise, it is of utmost 
importance to make HPV vaccination more aﬀ ordable 
everywhere, and to counter the pervasive myths about 
the safety of HPV vaccines. In addition to these eﬀ orts 
is the untapped potential to integrate HPV education 
and immunisation within adolescent health services, 
and within the broader framework of healthy lifestyle 
promotion. Such approaches are well aligned with the 
target in WHO’s Global Action Plan for the Prevention 
and Control of Non-communicable Diseases (NCDs)3 
for a 25% reduction in mortality from NCDs by 2025, 
and with the health-related targets of the Sustainable 
Development Goals to reduce by a third premature 
mortality from NCDs by 2030, and to improve access 
to safe and eﬀ ective vaccines and to sexual and 
reproductive health services.4 Women with HIV have a 
four to ﬁ ve times increased risk of developing cervical 
cancer.5 As such, regions with a high HIV prevalence 
should aim to integrate HIV and HPV education and 
services, including cervical screening and treatment 
of precancerous lesions, while rapidly scaling up HPV 
immunisation programmes. 
Also needed is better alignment, if not integration, 
between the advocacy movements for girls’ and women’s 
rights with those for women’s cancers. The 2016 Women 
Deliver Conference held in Copenhagen, Denmark, was 
a great success, advancing the economic and political 
empowerment agenda, and advocating for the health 
and wellbeing of girls and women globally. However, a 
plenary session addressing HPV, cervical cancer, or NCDs 
more broadly was absent, despite this being the year of 
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the UN Secretary General’s historic statement on World 
Cancer Day, in which he called for “the elimination of 
cervical cancer as a public health issue”.6 
The global cancer community has much to learn 
from the successful movements focused on women’s 
empowerment, sexual and reproductive rights, maternal 
health, and HIV/AIDS. Likewise, these communities 
should embrace advocates for cervical and other 
women’s cancers, rather than perceiving such groups 
as potential competitors for limited emotional and 
ﬁ nancial bandwidth. The time is long overdue for each 
to consider and engage the other as partners, colleagues, 
and collaborators to ensure—in the words of the new 
Every Women Every Child Global Strategy—that every 
woman and every child not only survives, but thrives.7 
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